News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
78,345 Results
Type
Article (7082)
Company Profile (17)
Press Release (71242)
Multimedia
Podcasts (14)
Webinars (1)
Section
Business (15891)
Career Advice (1121)
Deals (2853)
Drug Delivery (23)
Drug Development (16188)
Employer Resources (37)
FDA (2065)
Job Trends (2385)
News (35619)
Policy (3261)
Tag
2027 Biotech Bay Standard (1)
2027 Pharm Country Standard (2)
Academia (515)
Accelerated approval (13)
Adcomms (8)
Allergies (30)
Alliances (4019)
ALS (55)
Alzheimer's disease (330)
Antibody-drug conjugate (ADC) (116)
Approvals (2221)
Artificial intelligence (130)
Autoimmune disease (79)
Automation (11)
Bankruptcy (27)
Best Places to Work (2154)
Biosimilars (48)
Biotechnology (5)
Bladder cancer (101)
Brain cancer (25)
Breast cancer (262)
Cancer (2211)
Cardiovascular disease (138)
Career advice (873)
Career pathing (17)
CAR-T (185)
CDC (4)
Cell therapy (384)
Cervical cancer (14)
Clinical research (14725)
Collaboration (442)
Company closure (1)
Compensation (190)
Complete response letters (4)
COVID-19 (1028)
CRISPR (32)
C-suite (128)
Cystic fibrosis (37)
Data (2568)
Depression (30)
Diabetes (220)
Diagnostics (829)
Digital health (4)
Diversity (1)
Diversity, equity & inclusion (6)
Drug discovery (54)
Drug pricing (34)
Drug shortages (3)
Duchenne muscular dystrophy (50)
Earnings (9054)
Editorial (17)
Employer branding (7)
Employer resources (35)
Events (13508)
Executive appointments (137)
FDA (3117)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (1)
Frontotemporal dementia (6)
Funding (412)
Gene editing (65)
Generative AI (8)
Gene therapy (185)
GLP-1 (298)
Government (776)
Grass and pollen (4)
Guidances (117)
Healthcare (2529)
HIV (34)
Huntington's disease (14)
IgA nephropathy (18)
Immunology and inflammation (82)
Immuno-oncology (26)
Indications (41)
Infectious disease (1102)
Inflammatory bowel disease (48)
Inflation Reduction Act (1)
Influenza (26)
Intellectual property (42)
Interviews (220)
IPO (1550)
IRA (5)
Job creations (416)
Job search strategy (738)
JPM (29)
Kidney cancer (8)
Labor market (40)
Layoffs (122)
Leadership (19)
Legal (484)
Liver cancer (30)
Longevity (4)
Lung cancer (306)
Lymphoma (285)
Machine learning (10)
Management (10)
Manufacturing (144)
MASH (38)
Medical device (1208)
Medtech (1215)
Mergers & acquisitions (1532)
Metabolic disorders (416)
Multiple sclerosis (92)
NASH (4)
Neurodegenerative disease (109)
Neuropsychiatric disorders (20)
Neuroscience (713)
Neurotech (1)
NextGen: Class of 2026 (744)
Non-profit (520)
Now hiring (6)
Obesity (161)
Opinion (85)
Ovarian cancer (86)
Pain (31)
Pancreatic cancer (68)
Parkinson's disease (80)
Partnered (9)
Patents (83)
Patient recruitment (149)
Peanut (11)
People (3838)
Pharmaceutical (9)
Pharmacy benefit managers (4)
Phase 1 (5259)
Phase 2 (6840)
Phase 3 (4804)
Pipeline (1795)
Policy (47)
Postmarket research (360)
Preclinical (1768)
Press Release (8)
Prostate cancer (94)
Psychedelics (15)
Radiopharmaceuticals (30)
Rare diseases (229)
Real estate (344)
Recruiting (20)
Regulatory (3319)
Reports (14)
Research institute (485)
Resumes & cover letters (232)
Rett syndrome (16)
RNA editing (2)
RSV (24)
Schizophrenia (42)
Series A (58)
Series B (53)
Sickle cell disease (41)
Special edition (11)
Spinal muscular atrophy (31)
Sponsored (15)
Startups (336)
Stomach cancer (6)
Supply chain (20)
Tariffs (21)
The Weekly (14)
Vaccines (314)
Venture capital (21)
Weight loss (109)
Women's health (15)
Worklife (12)
Date
Today (6)
Last 7 days (162)
Last 30 days (541)
Last 365 days (8972)
2026 (780)
2025 (9079)
2024 (6991)
2023 (6096)
2022 (7293)
2021 (7797)
2020 (6978)
2019 (5173)
2018 (3833)
2017 (3818)
2016 (3161)
2015 (3714)
2014 (2239)
2013 (1539)
2012 (1653)
2011 (1651)
2010 (1203)
Location
Africa (213)
Alabama (15)
Arizona (20)
Arkansas (2)
Asia (5357)
Australia (1097)
California (3174)
Canada (715)
China (387)
Colorado (85)
Connecticut (133)
Delaware (155)
Europe (13216)
Florida (253)
Georgia (67)
Hawaii (2)
Idaho (10)
Illinois (263)
India (10)
Indiana (93)
Iowa (14)
Japan (179)
Kansas (7)
Kentucky (7)
Louisiana (4)
Maine (7)
Maryland (358)
Massachusetts (2432)
Michigan (52)
Minnesota (98)
Mississippi (2)
Missouri (44)
Nebraska (1)
Nevada (37)
New Hampshire (14)
New Jersey (1023)
New Mexico (3)
New York (857)
North Carolina (234)
North Dakota (3)
Northern California (1523)
Ohio (74)
Oregon (11)
Pennsylvania (467)
Puerto Rico (3)
Rhode Island (11)
South America (210)
South Carolina (13)
Southern California (1212)
Tennessee (33)
Texas (550)
United States (10666)
Utah (33)
Virginia (62)
Washington D.C. (13)
Washington State (281)
West Virginia (1)
Wisconsin (40)
78,345 Results for "t2 biosystems".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
CAR-T
Regeneron Cans 2seventy-Acquired CAR T Candidate for Lymphoma in ‘Strategic’ Move
The discontinued CAR T therapy bbT369 came to Regeneron when the pharma bought all of 2seventy bio’s pipeline assets for $5 million upfront in January 2024.
October 24, 2025
·
2 min read
·
Tristan Manalac
Genetown
T2 Biosystems Announces the Conversion of an Additional $15 Million of CRG Term Loan into Equity
T2 Biosystems, Inc., a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced the conversion of an additional $15 million of its term loan with entities affiliated with CRG Servicing LLC into T2 Biosystems equity.
May 6, 2024
·
4 min read
Genetown
T2 Biosystems Announces Commercial Expansion Through Hong Kong and Macau Distributor
T2 Biosystems, Inc., a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, announced the execution of a territory exclusive distribution agreement in Hong Kong and Macau.
June 25, 2024
·
4 min read
Genetown
T2 Biosystems Announces New Publication Highlighting the Clinical Benefits and Performance of the T2Resistance Panel
T2 Biosystems, Inc. today announced the publication of a new study highlighting the clinical benefits and performance of real-world use of the T2Resistance® Panel in The Journal of Clinical Microbiology.
March 18, 2024
·
5 min read
Genetown
T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business UpdatesAnticipates commercial launch of the T2Lyme Panel in the third quarter of 2024
T2 Biosystems, Inc. today announced plans for the T2Lyme Panel commercial launch and provided recent business updates.
March 20, 2024
·
5 min read
Press Releases
Trailhead Biosystems Expands Financing to $40 Million
January 13, 2026
·
2 min read
Genetown
T2 Biosystems Announces Commercial Expansion Through Middle East Distributor
T2 Biosystems, Inc., a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, announced the execution of a territory exclusive distribution agreement in Qatar.
May 6, 2024
·
5 min read
Business
T2 Biosystems Announces First Quarter 2024 Financial Results
T2 Biosystems, Inc., a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced unaudited financial and operational results for the first quarter ended March 31, 2024.
May 6, 2024
·
10 min read
Deals
T2 Biosystems Regains Compliance with Nasdaq Continued Listing Requirements
T2 Biosystems, Inc. today announced that it received written notice from the Nasdaq Stock Market LLC (“Nasdaq”) on May 21, 2024 informing the Company that it has regained compliance with the market value of listed securities (“MVLS”) requirement, as set forth in Nasdaq Listing Rule 5550(b)(2) (the “Rule”).
May 22, 2024
·
4 min read
Deals
T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirement
T2 Biosystems, Inc. today announced that the Nasdaq Hearings Panel has granted the Company’s request for continued listing on the Nasdaq Stock Market.
March 12, 2024
·
4 min read
1 of 7,835
Next
